Navigation Links
Boston Scientific Announces Schedule for European Society of Cardiology Congress
Date:8/27/2009

stem compared to bare-metal stenting in patients experiencing an acute myocardial infarction (AMI). Results will focus on the relative impact of ischemic complications and varying definitions of major bleeding on one-year mortality in patients with AMI.

Monday, August 31

  • Clinical Seminar - The SYNTAX Trial: One Year On. The Company will sponsor a clinical seminar chaired by Miguel Sousa Uva, M.D., and Antonio Colombo, M.D., from 4:30-6:00 p.m. in the Madrid Room. Discussion topics will include the view of the non-interventional cardiologist and conclusions from subgroup analyses.

Tuesday, September 1

  • MADIT-CRT Trial Data. Final results from the MADIT-CRT trial will be presented by Arthur Moss, M.D., during a Hot Line presentation session at 12:15 p.m. in the Barcelona Room. The MADIT-CRT trial has more than 1,800 patients and examines whether early intervention with cardiac resynchronization therapy in high-risk, New York Heart Association Class I and II patients slows the progression of heart failure when compared to implantable cardioverter defibrillator (ICD) therapy. The Company plans to issue a press release simultaneous with an ESC press conference, which begins at 8:00 a.m.

  • Analyst Conference Call. The Company will webcast a conference call beginning at 2:00 p.m. to discuss final results from the MADIT-CRT trial. The live webcast and archived replay of this call will be available at www.bostonscientific.com in the Investor Relations section. The webcast is also being distributed over Thomson Financial's Investor Distribution Network via two locations: www.
    '/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
2. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
3. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
4. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
5. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
6. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
7. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
8. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
9. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
10. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
11. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015   Synthetic Biologics, Inc. ... on protecting the microbiome, as well as treating other ... appointed Chief Financial Officer, Treasurer and Secretary effective June ... who will be leaving the Company in May to ... Synthetic Biologics operational, financial and international biotech industry experience, ...
(Date:5/4/2015)... BOULDER, Colo., May 4, 2015  Array BioPharma ... for the third quarter of its fiscal year ... Chief Executive Officer of Array, noted, "With the close ... binimetinib and encorafenib, two innovative oncology products in ... each product in 2016. These transformative transactions have ...
(Date:5/4/2015)... , May 4, 2015 ... has granted an Orphan Drug Designation (ODD) for rimeporide, ... dystrophy (DMD). DMD is a rare, life-threatening disease affecting ... muscle loss. It is the most common and serious ... a selective sodium/proton exchanger type-1 inhibitor, originally developed by ...
Breaking Medicine Technology:Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 2Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 10EspeRare's Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy 2
(Date:5/4/2015)... In response to the proposed mammography ... (USPSTF), Strategic Radiology® (SR®) fully aligns itself with ... Gynecologists (ACOG), the American College Of Surgeons, Susan ... (ACS), American College of Radiology (ACR), and Society ... screening mammography for women beginning at age 40 ...
(Date:5/4/2015)... For partners who’d like to become parents, Astroglide ... TTC™ (Trying to Conceive) . Unlike traditional lubricants that ... TTC™ is specially formulated to provide a better environment ... Disease Control, an average of one in eight ... pregnancy, and over 7.4 million women have ...
(Date:5/4/2015)... 04, 2015 Fast on the heels ... Trace Amounts, and Allison Folmar, JD, join over 150 ... internationally. , On Sunday, May 24, the conference presents ... possible?" Are you interested in Ryan Hinds' recovery story? ... our war against autism was written by Marcia ...
(Date:5/4/2015)... 2015 “St. Louis has long represented ... the West,” so it is the perfect place for ... Dr. Ben Litalien, Chief Development Officer for Zerorez. ... and will provide veterans with a $10,000 discount on ... to have a number of Military Veterans in its ...
(Date:5/3/2015)... 03, 2015 AvePoint, ... platforms and devices, today announced it is a ... Professionals (IAPP) Asia Privacy Forum, taking place May ... the event, AvePoint will showcase its compliance, risk, ... platforms. , Visit AvePoint for New Solutions ...
Breaking Medicine News(10 mins):Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 4
... hernias are one of the most common conditions treated ... annually. Although ventral hernia repair (VHR) is a common ... infection has been identified as a consistent risk factor ... which appears in the November issue of The ...
... such as Viagra use is linked to development of vision ... disorders have used Viagra medicines. It is found that it ... cause risk of blindness. Men most at risk for the ... heart disease, high blood pressure and high cholesterol, among other ...
... Findings presented at the American Society of Therapeutic Radiation ... antigen (PSA) // significantly reduces the mortality associated with ... most prevalent type of cancer found in men after ... in the male reproductive system, which produces some of ...
... is essential for the lipid and carbohydrate metabolism, and ... to insulin.// The use of glucose by the peripheral ... has potential impact on long-term complications. ,In ... and an association between the proper metabolic control and ...
... and colleagues have identified a candidate gene, Sipa1, ... in cancer. Cancer mortality is most often the ... studies from Kent Hunter’s group demonstrated that the ... efficiency. They expressed the polyoma middle-T transgene in ...
... in women after menopause has been found to enhance ... cholesterol (the “good” cholesterol) in women, according to a ... and is characterized by decreased levels of the female ... the vagina and uterus. In addition the hormone ...
Cached Medicine News:Health News:Predictors Of Wound Infection In Ventral Hernia Repair 2Health News:Impotence drug such as Viagra may cause Vision Loss 2Health News:Carnitine deficiency in children and adolescents with type 1 diabetes 2Health News:Researchers Identify Sipa 1 Gene, Responsible For Cancer Metastasis 2Health News:Testosterone Therapy can improve sexual function in postmenopausal women 2
Gentamicin is a selection antibiotic used for selection of a Bac-to-Bac recombinant expression bacmid following transposition. Gentamicin is provided as a solution at a concentration of 50 mg/ml....
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 1.5% agarose....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride, 1.5% agar....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Medicine Products: